HC Wainwright Downgrades Savara (NASDAQ:SVRA) to Neutral

HC Wainwright downgraded shares of Savara (NASDAQ:SVRA) from a buy rating to a neutral rating in a research note released on Thursday morning, MarketBeat.com reports. The firm currently has $2.00 price objective on the stock, down from their prior price objective of $6.00. HC Wainwright also issued estimates for Savara’s FY2029 earnings at $0.08 EPS.

Several other analysts have also issued reports on the stock. Guggenheim restated a “buy” rating and set a $8.00 price target (down from $9.00) on shares of Savara in a research report on Wednesday. Evercore ISI lowered their price objective on shares of Savara from $3.00 to $2.00 and set an “in-line” rating for the company in a research note on Wednesday. Finally, Wells Fargo & Company lowered their price objective on shares of Savara from $8.00 to $7.00 and set an “overweight” rating for the company in a research note on Wednesday. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.17.

Savara Stock Performance

NASDAQ SVRA opened at $2.29 on Thursday. The company has a 50-day simple moving average of $2.92 and a two-hundred day simple moving average of $2.94. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara has a 12-month low of $1.89 and a 12-month high of $5.11. The firm has a market cap of $395.80 million, a price-to-earnings ratio of -5.33 and a beta of 0.44.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). On average, equities analysts forecast that Savara will post -0.45 EPS for the current year.

Hedge Funds Weigh In On Savara

Several hedge funds and other institutional investors have recently modified their holdings of the company. Bain Capital Life Sciences Investors LLC raised its stake in shares of Savara by 20.8% during the first quarter. Bain Capital Life Sciences Investors LLC now owns 17,600,621 shares of the company’s stock valued at $48,754,000 after acquiring an additional 3,035,164 shares during the last quarter. Frazier Life Sciences Management L.P. raised its stake in Savara by 32.4% in the first quarter. Frazier Life Sciences Management L.P. now owns 11,462,301 shares of the company’s stock worth $31,751,000 after buying an additional 2,801,922 shares in the last quarter. Vestal Point Capital LP raised its stake in Savara by 2.1% in the first quarter. Vestal Point Capital LP now owns 11,000,000 shares of the company’s stock worth $30,470,000 after buying an additional 225,000 shares in the last quarter. Vanguard Group Inc. raised its stake in Savara by 4.6% in the fourth quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company’s stock worth $25,512,000 after buying an additional 365,959 shares in the last quarter. Finally, Nantahala Capital Management LLC raised its stake in Savara by 7.3% in the first quarter. Nantahala Capital Management LLC now owns 8,075,375 shares of the company’s stock worth $22,369,000 after buying an additional 550,116 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.